FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C	. 20549
-----------------	---------

OMB APPROVAL									
OMB Number: 3235-02									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					UI.	Secur	JII 30(II) C	JI LIIC	invesiment C	ompany Act	01 1940							
1. Name and Address of Reporting Person* <u>Abraham William Tober</u>					2. Issuer Name and Ticker or Trading Symbol scPharmaceuticals Inc. [SCPH]						(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
				1								X Directo	or		10% Ov	/ner		
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 06/08/2021							Officer below)	(give title		Other (s below)	pecify	
C/O SCPHARMACEUTICALS INC, 2400				1														
DISTRICT AVENUE, SUITE 310					4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable					
(Street)					1							Line	,	:11	D	utina Davas	.	
BURLINGTON MA 01803												X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State) (Zip)							1 61301											
		Tab	le I - Non	-Deriva	ative	e Sec	curities	s Ac	quired, Di	sposed o	of, or Be	neficiall	y Owned					
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution Date,		Code (Instr. 5)			ed (A) or tr. 3, 4 and	Benefici	es Formally (D) (Following (I) (I		m: Direct	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
						Code V	Amount	(A) oi (D)	Price	Transact (Instr. 3	tion(s)			(111341.4)				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
				c	Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$5.7	06/08/2021			A		16,300		(1)	06/08/2031	Common Stock	16,300	\$0.00	16,300		D		

Explanation of Responses:

1. This stock option vests in full upon the earlier of (i) June 8, 2022, and (ii) the next annual meeting of the Issuer's stockholders.

Remarks:

/s/ John H. Tucker, attorney-in-06/10/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.